Norepinephrine for Prevention of Intraoperative Hypotension in Infants Undergoing Kasai Portoenterostomy
Primary Purpose
Anesthesia, Pediatrics, Biliary Atresia
Status
Recruiting
Phase
Phase 3
Locations
Egypt
Study Type
Interventional
Intervention
Norepinephrine Bitartrate
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Anesthesia focused on measuring Kasai, biliary atresia, norepinephrine, hypotension
Eligibility Criteria
Inclusion Criteria:
- Infants, ASA III, diagnosed as biliary atresia undergoing Kasai operation.
Exclusion Criteria:
- Parents refusal. Patients with complex cardiac anomalies. Patients requiring emergency or laparoscopic procedures.
Sites / Locations
- Cairo university hospitalsRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
(Group N)
(Group S)
Arm Description
1 mg norepinephrine will be diluted in dextrose 5% in a 50 mL syringe using a nomogram based on the infant body weight so that 1mL= 0.05 µg/kg/min norepinephrine infusion and the syringe will be set on 2 ml/h
equivalent volume of saline will be prepared in 50 mL syringe and the infusion will be set on 2ml/kg
Outcomes
Primary Outcome Measures
Incidence of intraoperative hypotension
Incidence of intraoperative hypotension defined as persistent reduction of mean ABP ≥20% of the baseline mean ABP recorder preoperatively requiring release of the liver after initial resuscitation.
Secondary Outcome Measures
mean arterial pressure (MAP)
mean arterial pressure (MAP) will be measured upon arrival to the operating room suite as baseline and every 5 minutes after induction of anesthesia and every 3 minutes during liver mobilization till the end of surgery.
heart rate
will be measured upon arrival to the operating room suite as baseline and every 5 minutes after induction of anesthesia and every 3 minutes during liver mobilization till the end of surgery.
Incidence of severe hypotension
Incidence of severe hypotension defined as reduction of mean ABP ≥30% of the baseline mean ABP recorder preoperatively.
Incidence of hypertension
Incidence of hypertension defined as increase of mean ABP ≥20% of the baseline
Total dose of rescue norepinephrine.
Total dose of rescue norepinephrine.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05521152
Brief Title
Norepinephrine for Prevention of Intraoperative Hypotension in Infants Undergoing Kasai Portoenterostomy
Official Title
Prophylactic Use of Norepinephrine for Prevention of Intraoperative Hypotension in Infants Undergoing Kasai Portoenterostomy Operation for Biliary Atresia: Double Blinded Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 1, 2022 (Actual)
Primary Completion Date
December 1, 2023 (Anticipated)
Study Completion Date
December 1, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Kasr El Aini Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study aims to assess the efficacy and safety of prophylactic intraoperative norepinephrine infusion versus the standard technique on decreasing the incidence of intraoperative hypotension in infants undergoing Kasai portoenterostomy operation.
Detailed Description
All children will be anesthetized in accordance with the local policy of pediatric anesthesia unit in Abu El-Reesh pediatric hospital-Cairo university.
Upon arrival to the operating room heart rate HR, noninvasive blood pressure NBP and oxygen saturation SPO2 will be monitored using standard monitor (Dräger infinity vista XL) before inhalational induction of anesthesia using titration of sevoflurane in oxygen air mixture 60% (starting from 3% up to 8%) until the child is put to sleep.
After securing an intravenous line anesthesia will be completed with 2µg/kg of fentanyl and atracurium 0.5 mg/kg to facilitate endotracheal intubation. Anesthesia will be maintained by using 1.2 % isoflurane in a mixture of oxygen and air (50/50) and atracurium top ups at a dose of 0.1mg/kg every 30 minutes. Mechanical ventilation will be set to volume-controlled mode TV:8ml/kg, I/E ratio:1/2, PEEP: 3 cmH2o and respiratory rate will be adjusted to maintain ETCO2 30-35 mmHg. Nasopharyngeal temperature probe will be inserted for monitoring of core body temperature. 22 G arterial cannula will be placed in the radial artery for continuous monitoring of arterial blood pressure and management of intraoperative hemodynamics.
Central venous catheter will be inserted under complete aseptic condition using ultrasound guidance and a Foley's catheter will be inserted in the urinary bladder.
The concealed envelopes will then be opened by an anesthesia resident (who will not be involved in patient management to ensure the blinding) and he will be responsible for preparing norepinephrine infusion or placebo as instructed in the envelope as follow:
(Group N): 1 mg norepinephrine will be diluted in dextrose 5% in a 50 mL syringe using a nomogram based on the infant body weight so that 1mL= 0.05 µg/kg/min norepinephrine infusion.
(Group S): equivalent volume of saline will be prepared in 50 mL syringe. In both groups the attending anesthetist will be instructed to set the 2 syringe pumps on 2 mL/h continuous infusion following skin incision.
Intraoperative fluid management:
All children will receive a loading dose of 10 ml/kg of lactated ringer solution over 10 minutes after induction of anesthesia and will be maintained on 10 ml/kg/h lactated ringer solution using an infusion pump. Dextrose 1% will be transfused in a separate line and rate will be adjusted according to blood glucose level.
Packed RBCs will be transfused at a dose of 15mL/kg if intraoperative Hb dropped to 8 gm/dL.
Intraoperative hemodynamic management:
Episodes of hypotension defined as reduction of the mean ABP ≥20% of the baseline mean ABP recorded preoperatively will be managed by boluses of lactated ringer solution of 10 mL/kg that will be repeated up to 30 mL/kg, if hypotension persisted, norepinephrine bolus of 0.01 µg/kg bolus will be given, if hypotension persisted after 2 boluses the surgery will be stopped and the liver will be released into the abdominal cavity until the BP is restored. Total dose of norepinephrine will be recorded.
Hypertension defined as increase of mean ABP ≥20% of the baseline mean arterial pressure ABP will be treated by stopping the infusion pump until ABP return to baseline and then the infusion will be resumed to 1 mL/h. Bradycardia defined as HR less than 80 beat/min will be managed by atropine 0.01mg/kg.
Following release of the liver the norepinephrine infusion will be stopped gradually guided by the mean ABP.
At the end of the procedure an open transverses abdominis plane block TAPB will be given using 5 mL bupivacaine 0.25% before skin closure, inhalational anesthesia will be discontinued, infusion will be stopped and reversal of muscle relaxation with atropine (0.02 mg/Kg) and neostigmine (0.05 mg/Kg) will be administered IV after return of patient's spontaneous breathing and patients will then be transferred to PICU.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anesthesia, Pediatrics, Biliary Atresia
Keywords
Kasai, biliary atresia, norepinephrine, hypotension
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
(Group N)
Arm Type
Experimental
Arm Description
1 mg norepinephrine will be diluted in dextrose 5% in a 50 mL syringe using a nomogram based on the infant body weight so that 1mL= 0.05 µg/kg/min norepinephrine infusion and the syringe will be set on 2 ml/h
Arm Title
(Group S)
Arm Type
Placebo Comparator
Arm Description
equivalent volume of saline will be prepared in 50 mL syringe and the infusion will be set on 2ml/kg
Intervention Type
Drug
Intervention Name(s)
Norepinephrine Bitartrate
Intervention Description
anesthesia resident (who will not be involved in patient management to ensure the blinding) will be responsible for preparing norepinephrine infusion or placebo as instructed in the envelope as follow: 1 mg norepinephrine will be diluted in dextrose 5% in a 50 mL syringe using a nomogram based on the infant body weight so that 1mL= 0.05 µg/kg/min norepinephrine infusion.
the attending anesthetist will be instructed to set the 2 syringe pumps on 2 mL/h continuous infusion following skin incision.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo
Primary Outcome Measure Information:
Title
Incidence of intraoperative hypotension
Description
Incidence of intraoperative hypotension defined as persistent reduction of mean ABP ≥20% of the baseline mean ABP recorder preoperatively requiring release of the liver after initial resuscitation.
Time Frame
4 hours
Secondary Outcome Measure Information:
Title
mean arterial pressure (MAP)
Description
mean arterial pressure (MAP) will be measured upon arrival to the operating room suite as baseline and every 5 minutes after induction of anesthesia and every 3 minutes during liver mobilization till the end of surgery.
Time Frame
4 hours
Title
heart rate
Description
will be measured upon arrival to the operating room suite as baseline and every 5 minutes after induction of anesthesia and every 3 minutes during liver mobilization till the end of surgery.
Time Frame
4 hours
Title
Incidence of severe hypotension
Description
Incidence of severe hypotension defined as reduction of mean ABP ≥30% of the baseline mean ABP recorder preoperatively.
Time Frame
4 hours
Title
Incidence of hypertension
Description
Incidence of hypertension defined as increase of mean ABP ≥20% of the baseline
Time Frame
4 hours
Title
Total dose of rescue norepinephrine.
Description
Total dose of rescue norepinephrine.
Time Frame
4 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Month
Maximum Age & Unit of Time
4 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Infants, ASA III, diagnosed as biliary atresia undergoing Kasai operation.
Exclusion Criteria:
Parents refusal. Patients with complex cardiac anomalies. Patients requiring emergency or laparoscopic procedures.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Khaled Sarhan, MD
Phone
+201020067816
Email
khaled.sarhan@kasralainy.edu.eg
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Khaled Sarhan, MD
Organizational Affiliation
Cairo University Hospitals
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cairo university hospitals
City
Cairo
ZIP/Postal Code
11559
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Khaled Sarhan, MD
Phone
+201020067816
Email
khaled.sarhan@kasralainy.edu.eg
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Norepinephrine for Prevention of Intraoperative Hypotension in Infants Undergoing Kasai Portoenterostomy
We'll reach out to this number within 24 hrs